NCT05043519View on ClinicalTrials.gov

Phase I/II Clinical Trial of NP41 for Cranial Nerve Fluorescence Imaging

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

August 31, 2023

Study Completion Date

December 31, 2023

Conditions
Cranial Nerve Injuries
Interventions
DRUG

FAM-NP41

The patients will be injected with FAM-NP41 in one dose intravenously 2 hours prior to the dural incision.

Sponsors
All Listed Sponsors
collaborator

Chinese Academy of Sciences

OTHER_GOV

lead

Peking University Third Hospital

OTHER

NCT05043519 - Phase I/II Clinical Trial of NP41 for Cranial Nerve Fluorescence Imaging | Biotech Hunter | Biotech Hunter